Maurice was discovered mid-swing from the ceiling fan, having just hurled a perfectly ripe banana at his Bloomberg terminal upon reading the latest headlines about Rocket Pharmaceuticals.
Listen, I’ve seen some weird market reactions in my time. I once watched investors panic-sell a stock because the CEO’s tie was slightly askew in an earnings call. But this? This might take the coconut. Last week, Rocket Pharmaceuticals (RCKT) got the FDA’s accelerated approval for KRESLADI, a gene therapy for severe Leukocyte Adhesion Deficiency-I in children. Essentially, they conquered a regulatory mountain that would make lesser biotech companies weep into their beakers. And how did the market respond? By slapping the stock down 8.9%.
I had to sit down. Then I had to stand up. Then I had to eat several bananas to process what I was seeing.
Here’s the thing about gene therapy, and why I think the market just committed a spectacular own-goal: this approval is not a finish line. It’s the starting line of a 100-meter sprint. And Rocket isn’t just running one race—they’re entering multiple heats across different disease categories. While everyone else is fixating on the short-term stock price action, they’re missing the actual forest because they’re too busy examining one tree that happens to have fallen over temporarily.
The Setup: A Company Built Like a Diversified Banana Plantation
Before we talk about why the market got this wrong, let’s talk about what Rocket actually is. Founded back in 1999, it’s a late-stage biotech company with a portfolio that would make a diversified farmer jealous. They’re not betting the farm on one therapy in one disease. They’re essentially running a boutique clinic for rare genetic disorders, using two primary methodologies: in vivo adeno-associated viral (AAV) programs and ex vivo lentiviral (LV) programs.
Think of it this way: if your typical biotech company is someone trying to grow a single super-productive banana tree, Rocket is more like someone who’s learned to cultivate different crops across different soil conditions. They’ve got programs for cardiac diseases (Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy, BAG3 Dilated Cardiomyopathy), blood disorders (LAD-I, Fanconi Anemia, Pyruvate Kinase Deficiency), and more in the pipeline. Some are in Phase 2, some in Phase 1, some still in preclinical stage.
The KRESLADI approval? That’s just the first fruit to ripen. And it ripened in the most valuable way possible—accelerated approval, which means the FDA basically said, “Yeah, this is so promising for kids with a devastating condition that we’re not going to make you wait.”
Why the Market Freaked Out (And Why They’re Being Dumb About It)
The stock was trading around $4.64 when Foxy flagged it, and it had that delicious 54.7% 20-day momentum that makes biotech investors sit up and notice. Then the FDA approval hit, and the stock crashed like a banana peel on a marble floor. Multiple news outlets reported it like it was a disappointment. “Stock Down Despite FDA Nod,” the headlines screamed. “Down 8.9% After FDA Approval,” they lamented.
I think what happened is this: the market had already priced in the KRESLADI approval. Maybe they expected the news weeks ago. Maybe they got spooked by the broader market sentiment around biotech. Maybe they just needed to sell something that day and this was it. Whatever the reason, they confused “approval happened” with “approval disappointed,” and that’s where the opportunity lives.
Here’s what actually matters: LAD-I is a rare disease, sure, but it’s devastating. We’re talking about kids whose immune systems don’t work properly because of a genetic defect. KRESLADI isn’t a niche product for the desperate—it’s a breakthrough therapy for an orphan disease with limited alternatives. And in the orphan disease space, the price you can command is typically quite generous because the patient population is small but the medical need is absolute.
More importantly, KRESLADI is just the first domino. The real prize—the thing that actually justifies the valuation Foxy is targeting—is the cardiac gene therapy pipeline. Danon disease, PKP2-ACM, BAG3-DCM. These are progressive cardiac conditions that currently have virtually no good treatment options. Imagine if you could go into the heart with a gene therapy, fix the underlying genetic defect, and stop the disease in its tracks. That’s not a niche market—that’s a blockbuster opportunity waiting to happen. These are bigger patient populations than LAD-I. Bigger addressable markets. More reimbursement potential.
The Financials: Why This Actually Makes Sense (If You Squint the Right Way)
Now, let’s talk about the stuff that keeps sensible investors up at night. Rocket’s burning cash like a monkey with a flamethrower. Free cash flow is negative $104.8 million annually. They’ve got a debt-to-equity ratio of 8.974, which would make most value investors break out in hives. No P/E ratio because they’re not profitable. Forward P/E is negative 2.72, which is fancy math for “they’re losing money.”
But here’s where context matters, and this is the part where I think most casual investors miss the actual forest. You cannot evaluate a late-stage biotech company using the same metrics you’d use for a mature pharmaceutical company or a consumer staple. It’s like judging a banana tree based on last year’s harvest when it’s still in the planting phase. The relevant question isn’t “Are they profitable now?” It’s “Can they reach profitability before their cash runs out?”
The debt-to-equity ratio is high, yes. But look at the beta: 0.574. That’s remarkably low for a biotech stock. For context, the broader market has a beta of 1.0. A beta under 0.6 suggests that Rocket’s stock price doesn’t swing wildly with market sentiment the way you’d expect for a company this speculative. That’s either a sign that the market doesn’t fully understand the volatility of the business, or it’s a sign that there’s actual fundamental stability here that the market recognizes.
And here’s the thing about cash burn: it’s only catastrophic if you run out of cash before you have revenue. With KRESLADI approved and generating revenue, with the cardiac pipeline potentially moving into trials that could attract partnership or licensing deals, with multiple programs at various stages—Rocket has what we call “optionality.” Each successful program de-risks the entire company. They don’t need all five programs to work. They need maybe two or three to work and to partner or license the others. That’s a fundamentally different risk profile than a company with one shot at success.
The Regulatory Tailwind: 2026 is Looking Spicy
Here’s what really gets me excited, and why I think Foxy is seeing the actual board while everyone else is staring at one chess piece. The gene therapy regulatory pathway is accelerating in 2026. We’re not in some hypothetical future anymore. This is happening now. FDA is increasingly comfortable with gene therapy data. They’ve shown they’ll grant accelerated approval for therapies that address serious unmet medical needs. And Rocket has multiple shots on goal.
The Danon disease program (RP-A501) is in Phase 2. That’s not theoretical. That’s not someday. That’s active right now. A successful Phase 2 could lead to Phase 3, which could lead to another FDA approval conversation. Same with the other cardiac programs as they advance. Each successful readout is a catalyst. Each partnership possibility is a catalyst. The market right now is trading on the assumption that KRESLADI is the whole story, and everything else is pie-in-the-sky speculation. I think that’s backwards. I think KRESLADI is proof of concept, and everything else is the actual opportunity.
The Valuation Setup: From $3.64 to $8.50 (And Beyond)
Foxy’s entry price was $4.64 and target is $8.50. We’re currently at $3.64, which means you’re buying at a 22% discount to the entry price Foxy was willing to pay. The stock has a 52-week high of $8.26, which means it’s technically possible for the market to value it at $8.50—they just did it not that long ago.
But here’s what’s interesting: the stock got hammered from around $8 down to $3.64 (where we are now) during the broader biotech selloff and sector rotation. This isn’t a company that lost its mojo. This is a company that got caught in a market tornado and is now trading at distressed prices while its actual fundamentals have improved (they got an FDA approval, after all).
Market cap is about $395 million. For a company with an approved gene therapy on the market, a Phase 2 program in a multi-organ disease, multiple other programs advancing through the pipeline, and licensing agreements with legitimate institutions (UCL, UC Berkeley, Temple University), that’s not an expensive valuation. It’s actually cheap. If any one of those cardiac programs works, we’re talking about a multi-billion-dollar opportunity. If two work, we’re talking about a company that gets acquired or becomes a major player.
The Risks (Because I’m Not Going to Lie to You)
Gene therapy is hard. Clinical trials fail. The cardiac programs could falter. The market could decide it hates biotech for another year or two. Rocket could burn through cash faster than expected and need to dilute shareholders with new offerings. The short ratio is 4.64%, which isn’t huge but suggests some skeptics out there who might be right.
And let’s be real: KRESLADI is indicated for severe LAD-I in children. It’s helping kids, which is wonderful, but it’s also a small population. The revenue will be meaningful but not transformative for a company this size. The real money is in the cardiac programs. If those don’t work, the story changes dramatically.
But here’s my take: the risk-reward at $3.64 is heavily skewed toward the upside. You’re paying distressed prices for a company with improved fundamentals. You’re buying into a pipeline with multiple shots at success. You’re betting on a regulatory environment that’s increasingly friendly to gene therapy. And you’re getting in before the next round of positive data.
Maurice’s Final Thought
This is what separates the traders from the investors. The traders looked at the stock and saw it go down after good news and panicked sold. The investors looked at the stock and saw a company with an FDA approval, a promising pipeline, a manageable balance sheet, and multiple catalysts on the horizon at a discount price. One group is going to be right, and one group is going to be kicking themselves in 18 months.
I know which group I’m sitting with.
Disclaimer: Trained Market Money, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys—no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.
Coming Next Week: Maurice investigates whether AI-chip companies are actually planting real seeds or just promising digital fruit. Which semiconductor plays have genuine growth and which ones are all peel?
Maurice’s Wisdom: “Sometimes the market yells at the tree for producing fruit. That just means more fruit for those patient enough to wait for the harvest.”
Trained Market Monkey 